Conditions: Overactive Bladder
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 20
Healthy volunteers: no

Brief summary:
This study will design an alternative urodynamic platform to better evaluate treatment effects of medications for overactive bladder. Part II is dependent on results of Part I and may not be conducted.

Detailed description:

Arms:
arm 1: Part I, Sequence 1: tolterodine tartrate crossing over to matching placebo arm 2: Part I, Sequence 2: placebo crossing over to study drug 4 mg once a Day (qd) arm 3: Part II, Sequence 1: study drug crossing over to placebo arm 4: Part II, Sequence 2: placebo crossing over to study drug

Interventions: intervention 1: tolterodine tartrate intervention 2: Comparator: Placebo to tolterodine tartrate
Intervention descriptions: intervention 1: Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days

Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days

Part IIb: single dose tolterodine tartrate 4 mg capsule intervention 2: Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days

Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days

Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule

Protocol document: